Blood-coagulation factor VIII
Blood-coagulation factor VIII structure
|
Common Name | Blood-coagulation factor VIII | ||
|---|---|---|---|---|
| CAS Number | 9001-27-8 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
|
Changes in the Factor VIII C2 domain upon membrane binding determined by hydrogen-deuterium exchange MS.
Biochem. J. 461(3) , 443-51, (2014) Factor VIII enhances the catalytic activity of Factor IXa in a membrane-bound enzyme complex and both proteins are necessary to prevent haemophilia. Tandem lectin-like C domains mediate the membrane binding of Factor VIII and membrane-interactive residues hav... |
|
|
Regeneration of cirrhotic liver in rabbits after intrahepatic injection of cryoprecipitate.
Bull. Exp. Biol. Med. 154(3) , 396-8, (2013) The stimulatory effect of cryoprecipitate on liver regeneration was studied in rabbits with cirrhosis of the liver induced by subcutaneous injection of tetrachloromethane. Cryoprecipitate stimulated the hepatocyte regeneration (appearance of binuclear and pro... |
|
|
Platelets and bleeding in the dental patient. It's not always from "blood thinners". Von Willebrand disease--clinical assessment and case report.
J. N. J. Dent. Assoc. 84(2) , 28-30, (2013)
|
|
|
An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
Ann. Hematol. 93(4) , 683-92, (2014) Haemophilia is characterised by defective thrombin generation, reduced clot stability and spontaneous bleeding. Treatment with factor VIII (FVIII) concentrate or bypassing agents (e.g. recombinant factor VIIa (rFVIIa)) is generally effective. Occasionally, ha... |
|
|
Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study.
JAMA Surg. 148(3) , 218-25, (2013) To quantify the impact of fibrinogen-containing cryoprecipitate in addition to the antifibrinolytic tranexamic acid on survival in combat injured.Retrospective observational study comparing the mortality of 4 groups: tranexamic acid only, cryoprecipitate only... |
|
|
Are current regulations for quality control of cryoprecipitate still appropriate for the 21st century?
Transfusion 54(12) , 3254-5, (2014)
|
|
|
In vitro efficacy of RiaSTAP after rapid reconstitution.
J. Surg. Res. 190(2) , 655-61, (2014) Fibrinogen is the first coagulation factor to reach critical levels during hemorrhage. Consequently, reestablishing normal fibrinogen levels is necessary to achieve adequate hemostasis. Fibrinogen is supplemented through administration of fresh frozen plasma,... |
|
|
Fibrinogen recovery and changes in fibrin-based clot firmness after cryoprecipitate administration in patients undergoing aortic surgery involving deep hypothermic circulatory arrest.
Transfusion 54(5) , 1379-87, (2014) Cryoprecipitate may be used to treat bleeding in cardiac surgery. Its effects on plasma fibrinogen and fibrin clotting in this setting are poorly defined.Patients undergoing on-pump aortic surgery with deep hypothermic circulatory arrest (DHCA) were recruited... |
|
|
Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy.
Transfusion 54(5) , 1389-405; quiz 1388, (2014) Fibrinogen plays a critical role in achieving and maintaining hemostasis and is fundamental to effective clot formation. There is increasing awareness of the important role of fibrinogen as a key target for the treatment and prevention of acquired bleeding. F... |
|
|
Genetic sequence analysis of inherited bleeding diseases.
Blood 122(20) , 3423-31, (2013) The genes encoding the coagulation factor proteins were among the first human genes to be characterized over 25 years ago. Since then, significant progress has been made in the translational application of this information for the 2 commonest severe inherited... |